Shield Thera Regulatory News (STX)

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

Block Listing Application

London, UK, 31 March 2022: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), has today made an application to the London Stock Exchange for a block listing of 2,000,000 ordinary shares of 1.5 pence each in the Company ("Block Listing Shares") to be admitted to trading on the London Stock Exchange ("Admission").

The 2,000,000 Block Listing Shares are to be issued under the Shield Therapeutics Retention and Performance Share Plan.

Admission is expected to occur on 06 April 2022.

For further information please contact:

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

Shield's lead product, Accrufer®/Feraccru®, has been approved for use in the United States, European Union, UK, Switzerland, and Australia and has exclusive IP rights until the mid-2030s. The Group has recently launched Accrufer® in the US. Feraccru® is being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Accrufer®/Feraccru® in China, Hong Kong, Macau, and Taiwan, Korea Pharma Co., Ltd. in the Republic of Korea and with KYE Pharmaceuticals Inc in Canada.

For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx